Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
Clinical trial NCT07004413 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07004413
- Sponsor
- Charite University, Berlin, Germany
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-10-01
- Primary completion
- 2028-10-01
- Enrollment
- 267
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.